Targeted therapy for small cell carcinoma of prostate: a case report
10.3760/cma.j.cn112330-20190722-00333
- VernacularTitle:前列腺小细胞癌靶向精准治疗1例报告
- Author:
Chenfei CHI
1
;
Jiazhou LIU
;
Liancheng FAN
;
Yongheng SHI
;
Zhixiang XIN
;
Jiahua PAN
;
Jianjun SHA
;
Yinjie ZHU
;
Wei XUE
;
Baijun DONG
Author Information
1. 上海交通大学医学院附属仁济医院泌尿科，上海 200127
- Keywords:
Prostatic neoplasms;
Neuroendocrine differentiation;
Individualized medicine
- From:
Chinese Journal of Urology
2022;43(4):299-300
- CountryChina
- Language:Chinese
-
Abstract:
A patient aged 68 years old presented urinary frequency, urgency, and gross hematuria for 1 month, with initial PSA of 72.72 ng/ml and alkaline phosphatase (ALP)of 114 U/L. Prostate biopsy pathology showed small cell neuroendocrine carcinoma of prostate. The patient was immediately administered 6 cycle of chemotherapy including etoposide and cisplatin combined with medical castration. The CDK4 gene was detected 1.99 times amplification by peripheral blood free DNA (cfDNA)gene analysis. The chemotherapy was followed by parbosini therapy. The number and density of bone metastases continued to decrease significantly by bone scan at 3 and 6 months after treatment, with a continuous decline of ALP and PSA. After 1 year of follow-up, pelvic MRI and bone systemic imaging indicated stable lesions, with PSA of 0.05 ng/ml and ALP of 59 U/L.
